Rapport Therapeutics Surges More Than 50% After Bipolar Mania Drug Meets All Trial Goals

Rapport Therapeutics shares jumped more than 50% on October 20 after the company announced that RAP-219 met both primary and secondary endpoints in a Phase 2 trial enrolling 253 adults with acute bipolar mania. By Week 3, patients on RAP-219 showed a statistically significant 3.1-point placebo-adjusted reduction on the Young Mania Rating Scale and a 0.4-point improvement on the Clinical Global Impressions for Bipolar Disorder scale. The drug also showed a clean safety profile, with zero severe or serious adverse events reported across the trial.

Several other clinical-stage companies reported meaningful trial updates on the same day. Revolution Medicines began dosing patients in the Phase 3 RASolve 308 study evaluating zoldonrasib combined with pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer. Odyssey Therapeutics reported that its Phase 2a ulcerative colitis trial of OD-001 met its primary endpoint. Leads Biolabs announced that its PD-L1/4-1BB bispecific antibody opamtistomig advanced to the expansion stage of a Phase 2 first-line gastric cancer study after a safety lead-in produced positive preliminary efficacy signals.

Additional data readouts included Nano24, which reported positive Phase 2b results for inhaled EXO-CD24 in acute respiratory distress syndrome at the CHEST Annual Meeting. Arcus Biosciences presented new data from its ARC-20 platform study showing casdatifan, a next-generation HIF-2alpha inhibitor, may serve as a foundational therapy across all lines of treatment in kidney cancer. Palisade Bio reported that five Crohn's disease patients treated with PALI-2108 for 14 days saw a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin. Teva and Sanofi also presented updated Phase 2b data at UEG Week showing their co-developed drug duvakitug maintained long-term positive outcomes in both ulcerative colitis and Crohn's disease.